CytomX Therapeutics (CTMX) Assets Average (2015 - 2026)

CytomX Therapeutics' Assets Average history runs 12 years deep, the most recent figure standing at $255.5 million for Q1 2026.

• Quarterly Assets Average rose 133.27% year-over-year to $255.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $255.5 million (up 133.27% YoY) and the FY2025 annual result came in at $136.0 million, down 15.58% from the prior year.
• Assets Average was $255.5 million for Q1 2026 at CytomX Therapeutics, up from $154.9 million in the prior quarter.
• Across five years, Assets Average topped out at $318.1 million in Q1 2022 and bottomed at $109.5 million in Q1 2025.
• A 5-year average of $202.8 million and a median of $211.5 million in 2023 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2025 — Assets Average plunged 43.33% — and 2026, when it surged 133.27%.
• CytomX Therapeutics' Assets Average stood at $243.7 million in 2022, then slipped by 13.22% to $211.5 million in 2023, then sank by 38.64% to $129.8 million in 2024, then increased by 19.38% to $154.9 million in 2025, then soared by 64.91% to $255.5 million in 2026.
• Business Quant data shows CTMX's Assets Average at $255.5 million in Q1 2026, $154.9 million in Q4 2025, and $166.7 million in Q3 2025.